Total
0
Shares
MyFiziq (ASX:MYQ) - CEO & Co Founder, Vlado Bosanac
CEO & Co Founder, Vlado Bosanac
Source: Balance The Grind
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MyFiziq (MYQ) will team up with Brazil’s Serfaty Clinic in an increased effort to combat the effects of obesity
  • Serfaty is the most prominent clinic in Brazil for obesity and diabetes treatment
  • It educates clients on preventive health and working with keto diets
  • Under the agreement, both companies will test and design MyFiziq’s technology for English and Portuguese users
  • Once they have found the best approach, it will be released to the Brazilian community
  • The companies believe the ongoing use of the application they are creating will have a far more reaching outcome, for both Brazil and the rest of the world
  • On the market today, Myfiziq is down 7.41 per cent and is trading for 12.5 cents per share

MyFiziq (MYQ) will team up with Brazil’s Serfaty Clinic in an increased effort to combat the effects of obesity.

The company announced today it has signed a letter of intent (LOI) with the clinic.

The Serfaty Clinic

Dr Alberto Serfaty opened up the Serfaty Clinic in the 1970’s. He was the first medical doctor in South America to work with ketogenic (keto) diets.

His clinic is now the biggest in Brazil for the treatment of obesity, diabetes and preventive health, working with keto diets and reversing all kinds of chronic diseases.

What is a keto diet?

The keto diet is a low-carb, high-fat diet. It involves drastically reducing carbohydrate intake and replacing it with fat. This reduction in carbs puts your body into a metabolic state called ketosis.

When this happens, your body becomes incredibly efficient at burning fat for energy. It also turns fat into ketones in the liver, which can supply energy for the brain

Believers reckon keto diets can cause massive reductions in blood sugar and insulin levels.

The partnership

The population of Brazil currently sits at 209 million people. Obesity in Brazil is a growing health concern, where 57.5 per cent of men and 48.2 per cent of women are overweight.

Under the agreement, both companies will test and design MyFiziq’s technology for English and Portuguese users. Once they have found the best approach, it will be released to the Brazilian community.

Alberto says he has been testing the MyFiziq technology for the past month and is pleased with how easy it is to use to assess his patients.

“This is a fantastic tool to not only identify the risk my patients are subjecting themselves too, but to also help them understand the trajectory they may be on whilst still relatively healthy,” he said.

“Obesity has a roll-on effect of so many chronic diseases that are directly now being correlated to the mortality rate of COVID-19,” he added.

COVID-19 and Obesity

There have been reports saying that people with obesity are more likely to have complications with COVID-19.

Zachary Bloomgarden, the Editor of the Journal of Diabetes, has released a call for all novel research surrounding COVID-19 and pneumonia symptoms for patients who also have Diabetes.

Bloomgarden has also stated that previous research on diabetes patients with influenza, SARS and MERS has shown the extra complications these patients experience.

In a recent public release, by The Obesity Society stated that the COVID-19 pandemic is challenging the world in unprecedented ways.

“We at Obesity have been sounding the alarm about the obesity epidemic and now must take up the cause for our patients with obesity in the face of this dual pandemic threat,” it stated.

“Obese people are at greater risk of serious complications from COVID-19 due to the increased risk of chronic diseases secondary to being overweight, such as some types of cancer and metabolic morbidities due to the increase in blood insulin levels,” Alberto explained.

What the partnership hopes to bring

The companies believe the ongoing use of the application they are creating will have a far more reaching outcome, for both Brazil and the rest of the world.

“With the current pandemic and increased mortality risk that has now been identified with obesity, we see this LOI as a priority,” MyFiziq CEO Vlado Bosanac said.

“Once deployed, we will look to demonstrate our findings to other Governments in light of the current concerns, so we can be at the front of these issues and the at-risk populations earlier in the disease cycle,” he added.

On the market today, Myfiziq is down 7.41 per cent and is trading for 12.5 cents per share at 1:54 pm AEST.

MYQ by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.